Clinical Trial Update: Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma [Phase 2]

View source ↗

Summary

Phase 2 trial updating the MUC1 peptide-poly-ICLC adjuvant vaccine in individuals with risk for colorectal cancer (advanced colorectal adenoma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Adenoma
• Colorectal Cancer
• Risk For Colorectal Cancer

Drugs mentioned

• MUC1 peptide-poly-ICLC adjuvant vaccine (MUC1 peptide-poly-ICLC adjuvant vaccine)

Snippet

Sponsor: Robert Schoen | Conditions: Risk for Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-02-03